GCC Biosimilar Market

1 Introduction
    1.1    Research Objectives 
    1.2    Stakeholders
    1.3    Scope of the Report
    1.4    Assumptions and Limitations
2 Research Methodology 
    2.1    Data Collection
        2.1.1    Primary Sources
        2.1.2    Secondary Sources
    2.2    Market Size Estimation
        2.2.1    Bottom-Up Approach
        2.2.2    Top-Down Approach
    2.3    Data Validation
3 Executive Summary
4 Introduction to Global Biosimilar Market
    4.1    Overview
    4.2    WHO and FDA Terminology on Biosimilars
    4.3    Biosimilars and Generics
    4.3    Biosimilars and Branded Biological Products
5 Biosimilar Research, Development and Manufacturing
    5.1    Research and Development: Biosimilars vs. Innovator Drugs
    5.2    Manufacturing: Biosimilars vs. Innovator Drugs
6 Global Biosimilar Market
    6.1    Historical Market Trends
    6.2    Market Segmentation by Region
    6.3    Market Outlook
7 GCC Biosimilar Market
    7.1    Industry Overview 
    7.2    Key Industry Developments
    7.3    Market Trends
        7.3.1    Key Market Indicators
        7.3.2    Historical Market Trends
        7.3.3    Impact of COVID-19
8 GCC Biosimilar Market Segmentation by Country
    8.1    Saudi Arabia  
        8.1.1    Historical Market Trends
        8.1.2    Market Outlook
    8.2    United Arab Emirates   
        8.2.1    Historical Market Trends
        8.2.2    Market Outlook
    8.3    Qatar 
        8.3.1    Historical Market Trends
        8.3.2    Market Outlook
    8.4    Kuwait 
        8.4.1    Historical Market Trends
        8.4.2    Market Outlook
    8.5    Oman  
        8.5.1    Historical Market Trends
        8.5.2    Market Outlook
    8.6    Bahrain  
        8.6.1    Historical Market Trends
        8.6.2    Market Outlook
9 GCC Biosimilar Market Segmentation by Module 
    9.1    Infliximab
        9.1.1    Historical Market Trends
        9.1.2    Market Outlook
    9.2    Insulin Glargine
        9.2.1    Historical Market Trends
        9.2.2    Market Outlook
    9.3    Epoetin Alfa
        9.3.1    Historical Market Trends
        9.3.2    Market Outlook
    9.4    Etanercept
        9.4.1    Historical Market Trends
        9.4.2    Market Outlook
    9.5    Filgrastim
        9.5.1    Historical Market Trends
        9.5.2    Market Outlook
    9.6    Somatropin
        9.6.1    Historical Market Trends
        9.6.2    Market Outlook
    9.7    Rituximab
        9.7.1    Historical Market Trends
        9.7.2    Market Outlook
    9.8    Follitropin Alfa
        9.8.1    Historical Market Trends
        9.8.2    Market Outlook
10 GCC Biosimilar Market Segmentation by Type of Manufacturing 
    10.1    In-House Manufacturing
        10.1.1    Historical Market Trends
        10.1.2    Market Outlook
    10.2   Contract Manufacturing
        10.2.1    Historical Market Trends
        10.2.2    Market Outlook
11 GCC Biosimilar Market Segmentation by Indication
    11.1    Auto-Immune Diseases
        11.1.1    Historical Market Trends
        11.1.2    Market Outlook
    11.2    Blood Disorder
        11.2.1    Historical Market Trends
        11.2.2    Market Outlook
    11.3    Diabetes
        11.3.1    Historical Market Trends
        11.3.2    Market Outlook
    11.4    Oncology
        11.4.1    Historical Market Trends
        11.4.2    Market Outlook
    11.5    Growth Deficiency 
        11.5.1    Historical Market Trends
        11.5.2    Market Outlook
    11.6    Female Infertility
        11.6.1    Historical Market Trends
        11.6.2    Market Outlook
12 GCC Biosimilar Industry: Market Dynamics
    12.1   Overview
    12.2   Strengths
    12.3   Weaknesses 
    12.4   Opportunities
    12.5   Threats
13 GCC Biosimilar Industry: Value Chain Analysis
    13.1   Overview
    13.2   Research and Development
    13.3   Raw Material Suppliers
    13.4   Inbound Logistics
    13.5   Production
    13.6   Marketing 
    13.7   Outbound Logistics
    13.8   Consumers 
14 GCC Biosimilar Industry: Porter’s Five Forces Analysis
    14.1   Overview
    14.2   Threat of New Entrants
    14.3   Threat of Substitutes
    14.4   Bargaining Power of Buyers
    14.5   Bargaining Power of Suppliers
    14.6   Intensity of Rivalry
15 Competitive Landscape
    15.1   Market Structure
    15.2   Key Players 
    15.3   Key Success Factors 
16 Key Player Profiles
 
List of Figures

Figure 1: Global: Biosimilar Market: Sales Value (in Million US$), 2017-2022
Figure 2: Global: Biosimilar Market: Segmentation by Region (in %), 2022
Figure 3: Global: Biosimilar Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 4: GCC: Biosimilar Market: Sales Value (in Million US$), 2017-2022
Figure 5: GCC: Biosimilar Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 6: GCC: Biosimilar Market: Segmentation by Country (in %), 2022
Figure 7: GCC: Biosimilar Market: Segmentation by Molecule (in %), 2022
Figure 8: GCC: Biosimilar Market: Segmentation by Type of Manufacturing (in %), 2022
Figure 9: GCC: Biosimilar Market: Segmentation by Indication (in %), 2022
Figure 10: Saudi Arabia: Biosimilar Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Saudi Arabia: Biosimilar Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 12: United Arab Emirates: Biosimilar Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: United Arab Emirates: Biosimilar Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 14: Qatar: Biosimilar Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Qatar: Biosimilar Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 16: Kuwait: Biosimilar Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Kuwait: Biosimilar Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 18: Oman: Biosimilar Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Oman: Biosimilar Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 20: Bahrain: Biosimilar Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Bahrain: Biosimilar Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 22: GCC: Biosimilar (Infliximab) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: GCC: Biosimilar (Infliximab) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 24: GCC: Biosimilar (Insulin Glargine) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: GCC: Biosimilar (Insulin Glargine) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 26: GCC: Biosimilar (Epoetin Alfa) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: GCC: Biosimilar (Epoetin Alfa) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 28: GCC: Biosimilar (Etanercept) Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: GCC: Biosimilar (Etanercept) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 30: GCC: Biosimilar (Filgrastim) Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: GCC: Biosimilar (Filgrastim) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 32: GCC: Biosimilar (Somatropin) Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: GCC: Biosimilar (Somatropin) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 34: GCC: Biosimilar (Rituximab) Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: GCC: Biosimilar (Rituximab) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 36: GCC: Biosimilar (Follitropin Alfa) Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: GCC: Biosimilar (Follitropin Alfa) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 38: GCC: Biosimilar (In-house Manufacturing) Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: GCC: Biosimilar (In-house Manufacturing) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 40: GCC: Biosimilar (Contract Manufacturing) Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: GCC: Biosimilar (Contract Manufacturing) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 42: GCC: Biosimilar (Auto-Immune Diseases) Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: GCC: Biosimilar (Auto-Immune Diseases) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 44: GCC: Biosimilar (Blood Disorder) Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: GCC: Biosimilar (Blood Disorder) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 46: GCC: Biosimilar (Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: GCC: Biosimilar (Diabetes) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 48: GCC: Biosimilar (Oncology) Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: GCC: Biosimilar (Oncology) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 50: GCC: Biosimilar (Growth Deficiency) Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: GCC: Biosimilar (Growth Deficiency) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 52: GCC: Biosimilar (Female Infertility) Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: GCC: Biosimilar (Female Infertility) Market Outlook: Sales Value (in Million US$), 2023-2028
Figure 54: GCC: Biosimilar Industry: Market Dynamics
Figure 55: GCC: Biosimilar Industry: Value Chain Analysis
Figure 56: GCC: Biosimilar Market: Porter’s Five Forces Analysis

List of Tables

Table 1: GCC: Biosimilar Market: Key Industry Highlights, 2022 and 2028
Table 2: GCC: Biosimilar Market Outlook: Segmentation by Country (in Million US$), 2023-2028
Table 3: GCC: Biosimilar Market Outlook: Segmentation by Molecule (in Million US$), 2023-2028
Table 4: GCC: Biosimilar Market Outlook: Segmentation by Type of Manufacturing (in Million US$), 2023-2028
Table 5: GCC: Biosimilar Market Outlook: Segmentation by Indication (in Million US$), 2023-2028
Table 6: GCC: Biosimilar Market Structure
Table 7: GCC: Biosimilar Market: Key Players